11alpha-Hydroxyprogesterone
Based on 1 Customer Validation
11alpha-Hydroxyprogesterone is a naturally occurring steroid hormone and an 11β-hydroxysteroid dehydrogenase (11β-HSD) inhibitor. 11alpha-Hydroxyprogesterone decreases FAK protein expression and regulates epithelial-mesenchymal transition, cell migration, and cell invasion. 11alpha-Hydroxyprogesterone exhibits antiandrogenic and blood pressure-regulating activities. 11alpha-Hydroxyprogesterone is used in the research of breast cancer and malaria.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.53%
- CAS 番号: 80-75-1
- 分子式: C21H30O3
- 分子量:330.46
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.4 μM
Compound: 1b
|
Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as inhibition of [1,2,6,7-3H]-cortisol to [3H]cortisone preincubated for 10 mins before substrate addition by scintillation counting
Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as inhibition of [1,2,6,7-3H]-cortisol to [3H]cortisone preincubated for 10 mins before substrate addition by scintillation counting
|
[PMID: 24074876] |
| HEK293 | IC50 |
0.63 μM
Compound: 1b
|
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as inhibition of [1,2,-3H]-cortisone to [3H]cortisol preincubated for 10 mins before substrate addition by scintillation counting
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as inhibition of [1,2,-3H]-cortisone to [3H]cortisol preincubated for 10 mins before substrate addition by scintillation counting
|
[PMID: 24074876] |
体外実験
In MDA-MB-231 cells, 11α-OHP (10 µM; 24 h) treatment directly increases E-cadherin levels and reduces vimentin expression[1].
11α-OHP (1-10 µM; 24 h) does not exhibit cytotoxic or proliferative effects on MDA-MB-231 cells[1].
11α-OHP treatment does not significantly alter E-cadherin or N-cadherin expression in MCF-7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231
-
Concentration:1 µM, 10 µM
-
Incubation Time:24 h
-
Result:Decreased the degree of migration by 13.2%.
Reduced transwell migration by 49.6% at 1 µM and 67.3% at 10 µM.
Decreased transwell invasion rate by 47.2% at 1 µM and 71.3% at 10 µM.
-
Cell Line:MDA-MB-231
-
Concentration:10 µM
-
Incubation Time:24 h
-
Result:Increased E-cadherin levels by 2.11-fold compared to control.
Decreased vimentin expression by 44.9% compared to control.
-
Cell Line:MDA-MB-231
-
Concentration:1 µM, 10 µM
-
Incubation Time:24 h
-
Result:Did not exhibit cytotoxic or proliferative effects.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FVB/N-Tg(MMTV-PyVT)634Mul/J (female, 10 weeks old)[1]
-
Dosage:60 mg/mouse
-
Administration:s.c.; over a 5-week period
-
Result:Did not significantly alter body weight or primary tumor growth.
Increased E-cadherin protein levels by 1.52-fold and claudin-1 levels by 1.51-fold in tumors.
Reduced vimentin levels by 34% in tumors.
Decreased FAK expression by 93.3% in tumors.
Reduced lung metastasis incidence by 15.5%.
Decreased FAK expression by 13% in lung tissues.
Increased E-cadherin and claudin-1 expression in lung tissues by 4.27-fold and 5.54-fold, respectively.
- Spheroid/Tumor Organoid Invasion Assay
- RNA extraction experimental
- Western Blot
- Scratch/Wound-Healing Migration Assay
- Ex Vivo Tissue Slice/Explant Invasion Assay
- Patient-Derived Organoid Invasion Assay
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Breast Cancer Modeling
- 3D Tumor Spheroid Invasion Assay
- Protocol For Protein Expression And Purification
- Matrigel Transwell/Boyden Chamber Invasion Assay
- Invadopodia/Fluorescent Gelatin Degradation Assay
- Zigmond Chamber Chemotaxis Assay
- Research Protocol for Endocrine Diseases
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Organotypic 3D Invasion Assay
- Cell invasion
- Matrigel/ECM Transwell Invasion Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
- 3D Collagen/Hydrogel Matrix Invasion Assay
化学情報
-
CAS 番号 80-75-1
-
性状 Solid
-
分子量 330.46
-
分子式 C21H30O3
-
Color White to off-white
-
SMILES
C[C@@]12[C@]3([H])[C@](CCC1=CC(CC2)=O)([H])[C@@]4([H])[C@](C[C@H]3O)([C@H](CC4)C(C)=O)C
-
別名
11alpha-Hydroxyprogesterone
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (302.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (294 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0261 mL | 15.1304 mL | 30.2608 mL | 75.6521 mL |
| 5 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL | 15.1304 mL | |
| 10 mM | 0.3026 mL | 1.5130 mL | 3.0261 mL | 7.5652 mL | |
| 15 mM | 0.2017 mL | 1.0087 mL | 2.0174 mL | 5.0435 mL | |
| 20 mM | 0.1513 mL | 0.7565 mL | 1.5130 mL | 3.7826 mL | |
| 25 mM | 0.1210 mL | 0.6052 mL | 1.2104 mL | 3.0261 mL | |
| 30 mM | 0.1009 mL | 0.5043 mL | 1.0087 mL | 2.5217 mL | |
| 40 mM | 0.0757 mL | 0.3783 mL | 0.7565 mL | 1.8913 mL | |
| 50 mM | 0.0605 mL | 0.3026 mL | 0.6052 mL | 1.5130 mL | |
| 60 mM | 0.0504 mL | 0.2522 mL | 0.5043 mL | 1.2609 mL | |
| 80 mM | 0.0378 mL | 0.1891 mL | 0.3783 mL | 0.9457 mL | |
| 100 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.7565 mL |
11alpha-Hydroxyprogesterone 関連分類
HY-W011243 関連分類
Powered by Bioz
Keywords
- 11alpha-Hydroxyprogesterone
- 80-75-1
- 11β-HSD
- FAK
- 11beta-hydroxysteroid dehydrogenase inhibitor
- MDA-MB-231 cells
- Plasmodium falciparum FabI
- MMTV-PyMT breast cancer model
- lung metastasis
- cell invasion
- cell migration
- Aspergillus terreus
- FAK protein expression
- epithelial-mesenchymal transition
- Inhibitor
- inhibitor
- inhibit